Edwards Lifesciences Corp (NYSE:EW) reported Wednesday second-quarter adjusted EPS of 70 cents, beating the consensus of 69 cents. The sales increased 7% (+8% on constant currency) to $1.632 billion, below the consensus of $1.653 billion. The company reported Transcatheter Aortic Valve Replacement (TAVR) sales of $1 billion, which grew 5%, or 6% on a constant currency basis. Edwards’ competitive position did not meaningfully change globally, although the company experienced some regional pressures, and pricing was maintained. The company also agreed to acquire JenaValve Technology, a company focused on the transcatheter treatment of aortic regurgitation (AR). Edwards anticipates FDA approval of the JenaValve Trilogy Heart Valve System in late 2025, which will represent the first approved therapy for patients suffering from AR. Building on an investment made in 2016, the company exercised its option to acquire Endotronix, a heart failure (HF) management ...